Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | SRC | P12931 | 8/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15577871 | 1.00 | NR1H2 (0.36) | NR1H2ALDH1A1MEN1KMT2ASRC | |
| SCHEMBL15577547 | 0.86 | — | — | |
| SCHEMBL17013204 | 0.85 | NR1H2 (0.39) | NR1H2MEN1KMT2ASRC | |
| SCHEMBL393307 | 0.85 | ALDH1A1 (0.38) | NR1H2ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL1861180 | 0.85 | ALDH1A1 (0.38) | NR1H2ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL1861179 | 0.85 | ALDH1A1 (0.38) | NR1H2ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL16853649 | 0.83 | ALDH1A1 (0.32) | NR1H2ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL1318992 | 0.82 | NR1H2 (0.40) | NR1H2ALDH1A1MEN1KMT2ASRC | |
| SCHEMBL14636816 | 0.82 | SRC (0.38) | NR1H2MEN1KMT2ASRC | |
| SCHEMBL14636814 | 0.82 | SRC (0.38) | NR1H2MEN1KMT2ASRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2895482-B1 | HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2016-10-19 | — | — | EP | disclosed |
| US-9315475-B2 | HIV protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-04-19 | — | — | US | disclosed |
| EP-2895482-A1 | HIV PROTEASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-07-22 | — | — | EP | disclosed |
| US-20140200197-A1 | HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-07-17 | — | — | US | disclosed |
| WO-2014043019-A1 | HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140200197-A1 | HIV PROTEASE INHIBITORS | SERPINB1, PREP, PRSS1 | NR1H2 2659/4885ALDH1A1 2437/4885MEN1 4390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.